Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGL-TX-PTDM
2024-518774-14-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-transplantation diabetes mellitus (PTDM) and chronic kidney disease (CKD) comparing Forxiga with Placebo (2 arms). Primary endpoint: Post-transplant diabetes mellitus incidence after 6 and 12 months follow-up. Planned start Mar 2026; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
post-transplantation diabetes mellitus (PTDM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-518774-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518774-14-00.